Aswin Hoffmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aswin Hoffmann has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Erik Traneus
RaySearch Laboratories AB
2 shared publications - Felix Horst
OncoRay—National Center for Radiation Research in Oncology
2 shared publications - Franciska Lebbink
OncoRay—National Center for Radiation Research in Oncology
2 shared publications Krishna Godino Padre
OncoRay—National Center for Radiation Research in Oncology
2 shared publications- Marisa Cobanaj
Helmholtz-Zentrum Dresden-Rossendorf
2 shared publications Stefan Menkel
OncoRay—National Center for Radiation Research in Oncology
2 shared publications
Latest Publications
- Open Access
- 19 November 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (22) , 225013
Spot-wise compensation of proton beam deflection and radiation field deformation in the transverse magnetic field of an in-beam MR scanner using a research version of a commercial treatment planning system
Objective . Magnetic resonance-integrated proton therapy (MRiPT) offers the potential for high-precision, image-guided particle therapy but is challenged by magnetic field (MF)-induced proton beam deflection and radiation field deformation. Unless compensated for, these effects compromise dose conformity and prohibit clinical implementation. This work aims to develop and experimentally validate a spot-wise compensation method capable of restoring proton dose distributions in the presence of a measured three-dimensional magnetic vector field map within a clinical treatment planning system (TPS). Approach . A spot-wise compensation framework was implemented in a research version of RayStation, a TPS commercially available for clinical use. The method compensates both lateral beam deflection and MF-induced radiation field deformation by shifting individual pencil-beam spots based on displacement vectors derived from dose calculations in water phantoms using the measured MF of an in-beam MR scanner integrated with a horizontal proton beamline. Two complementary strategies were implemented: a patient-specific approach based on plan-specific displacement calculations, and a generic approach using precomputed displacement maps derived from a reference phantom. Compensation performance was evaluated in representative clinical cases. Dose distributions were experimentally validated using 2D ionisation chamber array measurements. Main results . Both compensation methods effectively restored target coverage, dose homogeneity, and organ-at-risk sparing to the level of no-MF reference plans. The patient-specific method generally achieved a higher performance, whereas the generic compensation method enabled rapid automated correction with sufficient accuracy for clinical workflows involving deep-seated tumours. Local γ -analysis demonstrated excellent agreement between measured and calculated doses, with pass rates exceeding 98.5% for 3%/3 mm criteria. Significance . This work demonstrates that compensation of MF-induced proton beam deflection and field deformation can be achieved entirely within a research version of the RayStation TPS using measured, MR scanner-specific MF data. The proposed method provides a scalable, robust framework for future MRiPT clinical applications.
- 19 November 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (22) , 225013
Open AccessSpot-wise compensation of proton beam deflection and radiation field deformation in the transverse magnetic field of an in-beam MR scanner using a research version of a commercial treatment planning system
Objective . Magnetic resonance-integrated proton therapy (MRiPT) offers the potential for high-precision, image-guided particle therapy but is challenged by magnetic field (MF)-induced proton beam deflection and radiation field deformation. Unless compensated for, these effects compromise dose conformity and prohibit clinical implementation. This work aims to develop and experimentally validate a spot-wise compensation method capable of restoring proton dose distributions in the presence of a measured three-dimensional magnetic vector field map within a clinical treatment planning system (TPS). Approach . A spot-wise compensation framework was implemented in a research version of RayStation, a TPS commercially available for clinical use. The method compensates both lateral beam deflection and MF-induced radiation field deformation by shifting individual pencil-beam spots based on displacement vectors derived from dose calculations in water phantoms using the measured MF of an in-beam MR scanner integrated with a horizontal proton beamline. Two complementary strategies were implemented: a patient-specific approach based on plan-specific displacement calculations, and a generic approach using precomputed displacement maps derived from a reference phantom. Compensation performance was evaluated in representative clinical cases. Dose distributions were experimentally validated using 2D ionisation chamber array measurements. Main results . Both compensation methods effectively restored target coverage, dose homogeneity, and organ-at-risk sparing to the level of no-MF reference plans. The patient-specific method generally achieved a higher performance, whereas the generic compensation method enabled rapid automated correction with sufficient accuracy for clinical workflows involving deep-seated tumours. Local γ -analysis demonstrated excellent agreement between measured and calculated doses, with pass rates exceeding 98.5% for 3%/3 mm criteria. Significance . This work demonstrates that compensation of MF-induced proton beam deflection and field deformation can be achieved entirely within a research version of the RayStation TPS using measured, MR scanner-specific MF data. The proposed method provides a scalable, robust framework for future MRiPT clinical applications.
- Open Access
- 7 October 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (19) , 195023
Dosimetric validation of proton beam deflection and field shape deformation in a measured transverse magnetic field of an in-beam MR scanner using a novel dose calculation functionality in a research version of a commercial treatment planning system
Objective. Integrating in-beam magnetic resonance imaging (MRI) with proton therapy (PT) introduces magnetic fields (MFs) that affect proton beam transport and therefore require accurate incorporation into the treatment planning system (TPS) for magnetic resonance (MR)-integrated PT (MRiPT). This study experimentally validates Monte Carlo-based proton dose calculation in the presence of the MF in a research version of the commercial TPS RayStation for MRiPT, using a measured three-dimensional (3D) magnetic vector field map of a 0.32 T in-beam MR scanner combined with a horizontal proton pencil beam scanning beam line. Approach. An MR-compatible mapping framework was used to acquire a high-resolution 3D magnetic vector field map, subsequently implemented into the TPS following coordinate transformations. Proton spot patterns and square radiation fields at 100, 150, and 220 MeV were delivered with and without the MF present. Dose distributions in air were measured using a 2D ionisation chamber array at multiple positions and compared with TPS dose calculations by analysing lateral beam shifts and field shape deformations with local γ -analysis. Clinically relevant patient treatment fields were evaluated at different water-equivalent depths (WEDs) in a phantom. Main results. Implementation of the measured magnetic vector field map preserved field vector magnitude, orientation and spatial alignment within the TPS. Dose measurements showed energy- and position-dependent MF-induced effects, which were accurately reproduced by the TPS. Agreement in lateral beam shifts was within 1–3 mm, and γ -pass rates exceeded 97% for a 3%/3 mm local criterion (10% dose threshold). Similar agreement was observed for patient treatment fields throughout all WEDs. Significance. This work validates the TPS capability to accurately model MF-induced proton beam transport in air as well as in a water-equivalent phantom. The present workflow establishes a foundation for proton treatment planning in the presence of MFs and thereby contributes to the clinical implementation of MRiPT.
- 7 October 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (19) , 195023
Open AccessDosimetric validation of proton beam deflection and field shape deformation in a measured transverse magnetic field of an in-beam MR scanner using a novel dose calculation functionality in a research version of a commercial treatment planning system
Objective. Integrating in-beam magnetic resonance imaging (MRI) with proton therapy (PT) introduces magnetic fields (MFs) that affect proton beam transport and therefore require accurate incorporation into the treatment planning system (TPS) for magnetic resonance (MR)-integrated PT (MRiPT). This study experimentally validates Monte Carlo-based proton dose calculation in the presence of the MF in a research version of the commercial TPS RayStation for MRiPT, using a measured three-dimensional (3D) magnetic vector field map of a 0.32 T in-beam MR scanner combined with a horizontal proton pencil beam scanning beam line. Approach. An MR-compatible mapping framework was used to acquire a high-resolution 3D magnetic vector field map, subsequently implemented into the TPS following coordinate transformations. Proton spot patterns and square radiation fields at 100, 150, and 220 MeV were delivered with and without the MF present. Dose distributions in air were measured using a 2D ionisation chamber array at multiple positions and compared with TPS dose calculations by analysing lateral beam shifts and field shape deformations with local γ -analysis. Clinically relevant patient treatment fields were evaluated at different water-equivalent depths (WEDs) in a phantom. Main results. Implementation of the measured magnetic vector field map preserved field vector magnitude, orientation and spatial alignment within the TPS. Dose measurements showed energy- and position-dependent MF-induced effects, which were accurately reproduced by the TPS. Agreement in lateral beam shifts was within 1–3 mm, and γ -pass rates exceeded 97% for a 3%/3 mm local criterion (10% dose threshold). Similar agreement was observed for patient treatment fields throughout all WEDs. Significance. This work validates the TPS capability to accurately model MF-induced proton beam transport in air as well as in a water-equivalent phantom. The present workflow establishes a foundation for proton treatment planning in the presence of MFs and thereby contributes to the clinical implementation of MRiPT.